The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 144, Issue 5, 2007, Pages 660-666

  Tyndale, Rachel F ^a,d   Payne, Jennifer I ^b   Gerber, Alexandra L ^c   Sipe, Jack C ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

9 tetrahydrocannabinol; Alcoholism; Pharmacogenetics; Sedatives; Smoking

Indexed keywords

ALCOHOL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; LIPID; NICOTINE; SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENE EXPRESSION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMODULATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE;

ADULT; ALCOHOL DRINKING; AMIDOHYDROLASES; CANADA; CANNABINOIDS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MARIJUANA SMOKING; MUTATION, MISSENSE; SMOKING; SUBSTANCE-RELATED DISORDERS;

CANNABIS; MAMMALIA; NICOTIANA TABACUM;

EID: 34447580198     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30491     Document Type: Article

References (33)

1. Beutler E, Gelbart T. 2000. Large-scale screening for HFE mutations: Methodology and cost. Genet Test 4(2):131-142.
2. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. 2002. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43(5):857-867.
3. Castane A, Berrendero F, Maldonado R. 2005. The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 81(2):381-386.
4. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. 2004. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13(18):2113-2119.
5. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. 2002. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13(5-6):451-463.
6. De Vries TJ, Schoffelmeer AN. 2005. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26(8):420-426.
7. Deutsch DG, Ueda N, Yamamoto S. 2002. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids 66(2-3):201-210.
8. Egertova M, Cravatt BF, Elphick MR. 2003. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119(2):481-496.
9. Fernandez JR, Allison DB. 2004. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 5(4):430-435.
10. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. 2004. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9(1):39-53.
11. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. 2005. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol 40(1):46-53.
12. Gonzalez S, Cebeira M, Fernandez-Ruiz J. 2005. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol Biochem Behav 81(2):300-318.
13. Hall WD, Lynskey M. 2005. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 24(1):39-48.
14. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. 2005. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30(2):339-349.
15. Howlett AC. 2002. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69:619-631.
16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161-202.
17. Ito H, Hamajima N, Matsuo K, Okuma K, Sato S, Ueda R, Tajima K. 2003. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics 13(2):73-79.
18. Jin Y, Chen D, Hu Y, Guo S, Sun H, Lu A, Zhang X, Li L. 2006. Association between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males. Int J Neuropsychopharmacol 9(5):955-964.
19. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76-81.
20. Lerman C, Caporaso NE, Bush A, Zheng YL, Audrain J, Main D, Shields PG. 2001. Tryptophan hydroxylase gene variant and smoking behavior. Am J Med Genet 105(6):518-520.
21. McGregor IS, Dam KD, Mallet PE, Gallate JE. 2005. Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. Alcohol Alcohol 40(1):35-45.
22. McKinney MK, Cravatt BF. 2005. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411-432.
23. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, Kishimoto M, Morio A, Imamura T, Sakai A, et al. 2005. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 376(3):182-187.
24. Patel S, Hillard CJ. 2006. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther. 318(1):304-311.
25. Rutkowska M, Jamontt J, Gliniak H. 2006. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58(2):200-206.
26. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. 2004. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14(9):615-626.
27. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. 2002. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99(12):8394-8399.
28. Sullivan PF, Jiang Y, Neale MC, Kendler KS, Straub RE. 2001. Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. Am J Med Genet 105(5):479-484.
29. Tanda G, Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276(5321):2048-2050.
30. Tyndale RF. 2003. Genetics of alcohol and tobacco use in humans. Ann Med 35(2):94-121.
31. Tyndale RF, Droll KP, Sellers EM. 1997. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7(5):375-379.
32. Vinod KY, Hungund BL. 2005. Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. Life Sci 77(14):1569-1583.
33. Wilhelmsen KC, Ehlers C. 2005. Heritability of substance dependence in a native American population. Psychiatr Genet 15(2):101-107.